Publications by Adil Mardinoglu
Refereegranskade
Artiklar
[1]
B. Yulug et al., "Combined metabolic activators improve cognitive functions in Alzheimer's disease patients : a randomised, double-blinded, placebo-controlled phase-II trial," Translational Neurodegeneration, vol. 12, no. 1, 2023.
[2]
H. Turkez et al., "Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases," Life Sciences, vol. 314, pp. 121325, 2023.
[3]
U. M. Battisti et al., "Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase," Nutrients, vol. 15, no. 3, pp. 577, 2023.
[4]
H. Turkez et al., "Lipoic Acid Conjugated Boron Hybrids Enhance Wound Healing and Antimicrobial Processes," Pharmaceutics, vol. 15, no. 1, pp. 149, 2023.
[5]
M. Yuan et al., "A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma," Cancers, vol. 14, no. 6, 2022.
[6]
N. Aydin et al., "Ameliorative Effects by Hexagonal Boron Nitride Nanoparticles against Beta Amyloid Induced Neurotoxicity," Nanomaterials, vol. 12, no. 15, pp. 2690, 2022.
[7]
A. Nain-Perez et al., "Anthraquinone derivatives as ADP-competitive inhibitors of liver pyruvate kinase," European Journal of Medicinal Chemistry, vol. 234, pp. 114270, 2022.
[8]
O. O. Tozlu et al., "Assessment of the neuroprotective potential of d-cycloserine and l-serine in aluminum chloride-induced experimental models of Alzheimer's disease : In vivo and in vitro studies," Frontiers in Nutrition, vol. 9, 2022.
[9]
H. Turkez et al., "Boron Compounds Exhibit Protective Effects against Aluminum-Induced Neurotoxicity and Genotoxicity : In Vitro and In Vivo Study," Toxics, vol. 10, no. 8, 2022.
[10]
O. C. Yildirim et al., "Boron Nitride Nanoparticles Loaded with a Boron-Based Hybrid as a Promising Drug Carrier System for Alzheimer's Disease Treatment," International Journal of Molecular Sciences, vol. 23, no. 15, 2022.
[11]
C. Zhang et al., "Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning," EBioMedicine, vol. 83, 2022.
[12]
C. Proffitt et al., "Genome-scale metabolic modelling of the human gut microbiome reveals changes in the glyoxylate and dicarboxylate metabolism in metabolic disorders," ISCIENCE, vol. 25, no. 7, pp. 104513, 2022.
[13]
M. Karlsson et al., "Genome-wide annotation of protein-coding genes in pig," BMC Biology, vol. 20, no. 1, 2022.
[14]
E. Mohammadi et al., "Improvement of the performance of anticancer peptides using a drug repositioning pipeline," Biotechnology Journal, vol. 17, no. 1, pp. 2100417, 2022.
[15]
M. E. Arslan et al., "In Vitro Transcriptome Analysis of Cobalt Boride Nanoparticles on Human Pulmonary Alveolar Cells," Materials, vol. 15, no. 23, 2022.
[16]
A. Tanas et al., "In Vitro and In Vivo Neuroprotective Effects of Sarcosine," BioMed Research International, vol. 2022, 2022.
[17]
S. Smati et al., "Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target," Gut, vol. 71, no. 4, pp. 807-821, 2022.
[18]
E. B. Emanuelsson et al., "MRI characterization of skeletal muscle size and fatty infiltration in long--term trained and untrained individuals," Physiological Reports, vol. 10, no. 14, 2022.
[19]
S. Lam et al., "Machine Learning Analysis Reveals Biomarkers for the Detection of Neurological Diseases," Frontiers in Molecular Neuroscience, vol. 15, 2022.
[20]
H. Turkez et al., "Molecular Genetics and Cytotoxic Responses to Titanium Diboride and Zinc Borate Nanoparticles on Cultured Human Primary Alveolar Epithelial Cells," Materials, vol. 15, no. 7, 2022.
[21]
A. T. Ambikan et al., "Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity," Cell Systems, vol. 13, no. 8, pp. 665-681.e4, 2022.
[22]
M. Zeybel et al., "Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis," Advanced Science, vol. 9, no. 11, pp. 2104373, 2022.
[23]
X. Li et al., "Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach," EBioMedicine, vol. 78, pp. 103963, 2022.
[24]
Z. Liu et al., "Recent Progress and Future Direction for the Application of Multiomics Data in Clinical Liver Transplantation," JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, vol. 10, no. 2, pp. 363-373, 2022.
[25]
M. Kori et al., "Repositioning of Anti-Inflammatory Drugs for the Treatment of Cervical Cancer Sub-Types," Frontiers in Pharmacology, vol. 13, 2022.
[26]
S. Yildirim et al., "Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort," mSystems, vol. 7, no. 1, 2022.
[27]
T. Basak et al., "Synthesis and in Vitro Toxicity Assessment of Different Nano-Calcium Phosphate Nanoparticles," Brazilian archives of biology and technology, vol. 65, 2022.
[28]
H. Turkez et al., "Therapeutic Potential of Ferulic Acid in Alzheimer's Disease," Current Drug Delivery, vol. 19, no. 8, pp. 860-873, 2022.
[29]
H. Turkez et al., "Toxicity of Glycyl-l-Prolyl-l-Glutamate Pseudotripeptides : Cytotoxic, Oxidative, Genotoxic, and Embryotoxic Perspectives," Journal of Toxicology, vol. 2022, pp. 1-8, 2022.
[30]
C. Y. Kahraman et al., "A Novel Mutation of ATP7B Gene in a Case of Wilson Disease," Medicina, vol. 57, no. 2, 2021.
[31]
H. Yang et al., "A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic liver disease," iScience, vol. 24, no. 11, 2021.
[32]
M. Karlsson et al., "A single-cell type transcriptomics map of human tissues," Science Advances, vol. 7, no. 31, 2021.
[33]
A. Harzandi et al., "Acute kidney injury leading to CKD is associated with a persistence of metabolic dysfunction and hypertriglyceridemia," iScience, vol. 24, no. 2, 2021.
[34]
S. Lam et al., "Addressing the heterogeneity in liver diseases using biological networks," Briefings in Bioinformatics, vol. 22, no. 2, pp. 1751-1766, 2021.
[35]
I. Cacciatore et al., "Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties," RSC Medicinal Chemistry, vol. 12, no. 11, pp. 1944-1949, 2021.
[36]
Ö. Altay et al., "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19," Advanced Science, vol. 8, no. 17, 2021.
[37]
H. Yang et al., "Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet," Biomedicines, vol. 9, no. 10, 2021.
[38]
M. Zeybel et al., "Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients," Molecular Systems Biology, vol. 17, no. 10, 2021.
[39]
X. Li et al., "Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers," Cancers, vol. 13, no. 2, 2021.
[40]
L. Andersson et al., "Glucosylceramide synthase deficiency in the heart compromises beta 1-adrenergic receptor trafficking," European Heart Journal, vol. 42, no. 43, pp. 4481-+, 2021.
[41]
H. Turkez et al., "Glycyl-L-Prolyl-L-Glutamate Pseudotripeptides for Treatment of Alzheimer's Disease," Biomolecules, vol. 11, no. 1, 2021.
[42]
H. Turkez et al., "In vitro transcriptome response to propolis in differentiated SH-SY5Y neurons," Journal of food biochemistry, vol. 45, no. 12, 2021.
[43]
J. R. Bosley et al., "Informing Pharmacokinetic Models With Physiological Data : Oral Population Modeling of L-Serine in Humans," Frontiers in Pharmacology, vol. 12, 2021.
[44]
M. Arif et al., "Integrative transcriptomic analysis of tissue-specific metabolic crosstalk after myocardial infarction," eLIFE, vol. 10, 2021.
[45]
L.-J. Zhao et al., "Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness," EMBO Reports, vol. 22, no. 8, 2021.
[46]
B. W. van der Kolk et al., "Molecular pathways behind acquired obesity : Adipose tissue and skeletal muscle multiomics in monozygotic twin pairs discordant for BMI," CELL REPORTS MEDICINE, vol. 2, no. 4, pp. 100226, 2021.
[47]
S. Doran et al., "Multi-omics approaches for revealing the complexity of cardiovascular disease," Briefings in Bioinformatics, vol. 22, no. 5, 2021.
[48]
W. Zhong et al., "Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms," EBioMedicine, vol. 74, pp. 103723, 2021.
[49]
A. Yazici et al., "Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells," Current Drug Delivery, vol. 18, no. 3, pp. 350-356, 2021.
[50]
H. Turkez et al., "Promising potential of boron compounds against Glioblastoma : In Vitro antioxidant, anti-inflammatory and anticancer studies," Neurochemistry International, vol. 149, 2021.
[51]
Ö. Altay et al., "Revealing the Metabolic Alterations during Biofilm Development of Burkholderia cenocepacia Based on Genome-Scale Metabolic Modeling," Metabolites, vol. 11, no. 4, 2021.
[52]
A. Bayraktar et al., "Revealing the Molecular Mechanisms of Alzheimer's Disease Based on Network Analysis," International Journal of Molecular Sciences, vol. 22, no. 21, 2021.
[53]
H. Turkez et al., "Safety and Efficacy Assessments to Take Antioxidants in Glioblastoma Therapy : From In Vitro Experiences to Animal and Clinical Studies," Neurochemistry International, vol. 150, 2021.
[54]
G. Alkurt et al., "Seroprevalence of coronavirus disease 2019 (COVID-19) among health care workers from three pandemic hospitals of Turkey," PLOS ONE, vol. 16, no. 3, 2021.
[55]
D. Mahdessian et al., "Spatiotemporal dissection of the cell cycle with single-cell proteogenomics," Nature, vol. 590, no. 7847, 2021.
[56]
X. Li et al., "Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning," iScience, vol. 24, no. 7, 2021.
[57]
D. Rosario et al., "Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease," Cell reports, vol. 34, no. 9, 2021.
[58]
A. Kaynar et al., "Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme," International Journal of Molecular Sciences, vol. 22, no. 24, pp. 13213, 2021.
[59]
E. Cinici et al., "Targeted Gene Candidates for Treatment and Early Diagnosis of Age-Related Macular Degeneration," BioMed Research International, vol. 2021, 2021.
[60]
C. Y. Kahraman et al., "The Assessment of Selected miRNA Profile in Familial Mediterranean Fever," BioMed Research International, vol. 2021, 2021.
[61]
M. Arif et al., "iNetModels 2.0 : an interactive visualization and database of multi-omics data.," Nucleic Acids Research, 2021.
[62]
S. Lam et al., "A systems biology approach for studying neurodegenerative diseases," Drug Discovery Today, vol. 25, no. 7, pp. 1146-1159, 2020.
[63]
A. Rawshani et al., "Adipose tissue morphology, imaging and metabolomics predicting cardiometabolic risk and family history of type 2 diabetes in non-obese men," Scientific Reports, vol. 10, no. 1, 2020.
[64]
M. J. Choi et al., "An adipocyte-specific defect in oxidative phosphorylation increases systemic energy expenditure and protects against diet-induced obesity in mouse models," Diabetologia, 2020.
[65]
[66]
E. Sjöstedt et al., "An atlas of the protein-coding genes in the human, pig, and mouse brain," Science, vol. 367, no. 6482, pp. 1090-+, 2020.
[67]
O. Özdemir et al., "Anticancer effects of novel NSAIDs derivatives on cultured human glioblastoma cells," Zeitschrift für Naturforschung C - A Journal of Biosciences, 2020.
[68]
E. Mohammadi et al., "Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning," Cancers, vol. 12, no. 9, 2020.
[69]
E. C. Sayitoglu et al., "Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D," Frontiers in Immunology, vol. 11, 2020.
[70]
X. Li et al., "Classification of clear cell renal cell carcinoma based on PKM alternative splicing," Heliyon, vol. 6, no. 2, 2020.
[71]
C. Lieven et al., "Correction: MEMOTE for standardized genome-scale metabolic model testing (vol 38, pg 272, 2020)," Nature Biotechnology, vol. 38, no. 4, pp. 504-504, 2020.
[72]
Ö. Altay et al., "Current Status of COVID-19 Therapies and Drug Repositioning Applications," iScience, vol. 23, no. 7, 2020.
[73]
H. Beklen et al., "Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer," Frontiers in Oncology, vol. 10, 2020.
[74]
I. Larsson et al., "Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development," Frontiers in Genetics, vol. 11, 2020.
[75]
H. Turkez et al., "Histidyl-Proline Diketopiperazine Isomers as Multipotent Anti-Alzheimer Drug Candidates," Biomolecules, vol. 10, no. 5, 2020.
[76]
M. Ozcan et al., "Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach," Advanced Biosystems, vol. 4, no. 6, 2020.
[77]
M. E. Arslan, H. Türkez and A. Mardinoglu, "In vitro neuroprotective effects of farnesene sesquiterpene on alzheimer’s disease model of differentiated neuroblastoma cell line," International Journal of Neuroscience, 2020.
[78]
C. Zhan et al., "Low Shear Stress Increases Recombinant Protein Production and High Shear Stress Increases Apoptosis in Human Cells," iScience, vol. 23, no. 11, 2020.
[79]
C. Lieven et al., "MEMOTE for standardized genome-scale metabolic model testing," Nature Biotechnology, vol. 38, no. 3, pp. 272-276, 2020.
[80]
R. Küçükdoğru et al., "Neuroprotective effects of boron nitride nanoparticles in the experimental Parkinson’s disease model against MPP+ induced apoptosis," Metabolic brain disease, 2020.
[81]
H. Turkez et al., "Nonpharmacological treatment options for Alzheimer's disease : from animal testing to clinical studies," Turkish Journal of Zoology, vol. 44, no. 2, pp. 81-89, 2020.
[82]
A. Pagoni et al., "Novel anti-Alzheimer phenol-lipoyl hybrids : Synthesis, physico-chemical characterization, and biological evaluation," European Journal of Medicinal Chemistry, vol. 186, 2020.
[83]
M. A. Chapman et al., "Skeletal Muscle Transcriptomic Comparison between Long-Term Trained and Untrained Men and Women," Cell reports, vol. 31, no. 12, 2020.
[84]
D. Rosario et al., "Systems Biology Approaches to Understand the Host-Microbiome Interactions in Neurodegenerative Diseases," Frontiers in Neuroscience, vol. 14, 2020.
[85]
C. Zhang et al., "The acute effect of metabolic cofactor supplementation : a potential therapeutic strategy against non-alc33oholic fatty liver disease," Molecular Systems Biology, vol. 16, no. 4, 2020.
[86]
K. Cadirci et al., "The in vitro cytotoxic, genotoxic, and oxidative damage potentials of the oral artificial sweetener aspartame on cultured human blood cells," Turkish Journal of Medical Sciences, vol. 50, no. 2, pp. 448-454, 2020.
[87]
M. Uhlén et al., "A genome-wide transcriptomic analysis of protein-coding genes in human blood cells," Science, vol. 366, no. 6472, pp. 1471-+, 2019.
[88]
M. Klevstig et al., "Cardiac expression of the microsomal triglyceride transport protein protects the heart function during ischemia," Journal of Molecular and Cellular Cardiology, vol. 137, pp. 1-8, 2019.
[89]
R. Benfeitas et al., "Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis," EBioMedicine, vol. 40, pp. 471-487, 2019.
[90]
S. Lundgren et al., "Discovery of KIRREL as a biomarker for prognostic stratification of patients within melanoma," Biomarker Research, 2019.
[91]
B. Turanli et al., "Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning," EBioMedicine, vol. 42, pp. 386-396, 2019.
[92]
C. Zhang et al., "Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling," Frontiers in Oncology, vol. 9, 2019.
[93]
M. C. Svensson et al., "Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival," Frontiers in Oncology, 2019.
[94]
C. Cadenas et al., "LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer," International Journal of Cancer, vol. 145, no. 4, pp. 901-915, 2019.
[95]
M. J. Harms et al., "Mature Human White Adipocytes Cultured under Membranes Maintain Identity, Function, and Can Transdifferentiate into Brown-like Adipocytes," Cell reports, 2019.
[96]
B. Turanli et al., "Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer," Frontiers in Genetics, vol. 10, 2019.
[97]
N. Sahebekhtiari et al., "Plasma Proteomics Analysis Reveals Dysregulation of Complement Proteins and Inflammation in Acquired Obesity-A Study on Rare BMI-Discordant Monozygotic Twin Pairs," PROTEOMICS - Clinical Applications, vol. 13, no. 4, 2019.
[98]
Z. Liu et al., "Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function," Metabolic engineering, 2019.
[99]
B. C. Turanli et al., "Systems biology based drug repositioning for development of cancer therapy," Seminars in Cancer Biology, 2019.
[100]
Ö. Altay et al., "Systems biology perspective for studying the gut microbiota in human physiology and liver diseases," EBioMedicine, vol. 49, pp. 364-373, 2019.
[101]
A. Mardinoglu et al., "The Potential Use of Metabolic Cofactors in Treatment of NAFLD," Nutrients, vol. 11, no. 7, 2019.
[102]
[103]
A. Mardinoglu et al., "An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans," Cell Metabolism, vol. 27, no. 3, pp. 559-571.e1-e5, 2018.
[104]
A. Lovric et al., "Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome," Scientific Reports, vol. 8, 2018.
[105]
J. Huvila et al., "Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma," Gynecologic Oncology, vol. 149, no. 1, pp. 173-180, 2018.
[106]
B. Turanli et al., "Drug Repositioning for Effective Prostate Cancer Treatment," Frontiers in Physiology, vol. 9, 2018.
[107]
C. Zhang et al., "ESS : A Tool for Genome-Scale Quantification of Essentiality Score for Reaction/Genes in Constraint-Based Modeling," Frontiers in Physiology, vol. 9, 2018.
[108]
A. Mardinoglu et al., "Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes," EBioMedicine, vol. 27, pp. 151-155, 2018.
[109]
L. Zamani et al., "High Cell Density Perfusion Culture has a Maintained Exoproteome and Metabolome," Biotechnology Journal, vol. 13, no. 10, 2018.
[110]
X. Zhang et al., "Identification of Discriminating Metabolic Pathways and Metabolites in Human PBMCs Stimulated by Various Pathogenic Agents," Frontiers in Physiology, vol. 9, 2018.
[111]
Z. Liu, A. Mardinoglu and S. Que, "Letter : dose-response analysis revealed closer relationship between obesity and perioperative outcomes in patients after liver transplantation," Alimentary Pharmacology and Therapeutics, vol. 47, no. 2, pp. 310-312, 2018.
[112]
Z. Liu et al., "Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome," Frontiers in Physiology, vol. 9, 2018.
[113]
G. Bidkhori et al., "Metabolic Network-Based Identification and Prioritization o f Anticancer Targets Based on Expression Data in Hepatocellular Carcinoma," Frontiers in Physiology, vol. 9, 2018.
[114]
G. Bidkhori et al., "Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes," Proceedings of the National Academy of Sciences of the United States of America, 2018.
[115]
A. Mardinoglu et al., "Systems biology in hepatology : approaches and applications," Nature Reviews. Gastroenterology & Hepatology, vol. 15, no. 6, pp. 365-377, 2018.
[116]
F. Danielsson et al., "Transcriptome profiling of the interconnection of pathways involved in malignant transformation and response to hypoxia," OncoTarget, vol. 9, no. 28, pp. 19730-19744, 2018.
[117]
E. Karnevi et al., "Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification," OncoTarget, vol. 9, no. 5, pp. 6188-6200, 2018.
[118]
D. Rosario et al., "Understanding the Representative Gut Microbiota Dysbiosis in Metformin-Treated Type 2 Diabetes Patients Using Genome-Scale Metabolic Modeling," Frontiers in Physiology, vol. 9, 2018.
[119]
L. Haversen et al., "Vimentin deficiency in macrophages induces increased oxidative stress and vascular inflammation but attenuates atherosclerosis in mice," Scientific Reports, vol. 8, 2018.
[120]
M. Uhlén et al., "A pathology atlas of the human cancer transcriptome," Science, vol. 357, no. 6352, pp. 660-+, 2017.
[121]
[122]
A. Mardinoglu and J. Boren, "AUP1 (Ancient Ubiquitous Protein 1) : A Molecular Link Between Hepatic Lipid Mobilization and VLDL Secretion," Arteriosclerosis, Thrombosis and Vascular Biology, vol. 37, no. 4, pp. 609-610, 2017.
[123]
J. Bosley et al., "Improving the economics of NASH/NAFLD treatment through the use of systems biology," Drug Discovery Today, vol. 22, no. 10, pp. 1532-1538, 2017.
[124]
S. Heinonen et al., "Mitochondria-related transcriptional signature is downregulated in adipocytes in obesity : a study of young healthy MZ twins," Diabetologia, vol. 60, no. 1, pp. 169-181, 2017.
[125]
S. Lee et al., "Network analyses identify liver-specific targets for treating liver diseases," Molecular Systems Biology, 2017.
[126]
A. Mardinoglu et al., "Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD," Molecular Systems Biology, vol. 13, no. 3, 2017.
[127]
A. Mardinoglu et al., "Plasma Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular Disease," Cell Metabolism, vol. 26, no. 2, pp. 281-283, 2017.
[128]
Z. Liu, S. Que and A. Mardinoglu, "Rediscussion on Linearity Between Fibrosis Stages and Mortality Risk in Nonalcoholic Fatty Liver Disease Patients," Hepatology, vol. 66, no. 4, pp. 1357-1358, 2017.
[129]
P. Sen, A. Mardinogulu and J. Nielsen, "Selection of complementary foods based on optimal nutritional values," Scientific Reports, vol. 7, no. 1, 2017.
[130]
S. Lee et al., "TCSBN: a database of tissue and cancer specific biological networks," Nucleic Acids Research, vol. 46, no. D1, pp. D595-D600, 2017.
[131]
Z. Liu et al., "The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C : a meta-analysis," Scientific Reports, vol. 7, 2017.
[132]
J. R. Casey et al., "Adaptive Evolution of Phosphorus Metabolism in Prochlorococcus," mSystems, vol. 1, no. 6, 2016.
[133]
S. Lee et al., "Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis," Nucleic Acids Research, vol. 44, no. 12, pp. 5529-5539, 2016.
[134]
A. Mardinoglu and J. Bosley, "Integrated Network Modeling for Novel Target Searches and Better Predictive Models," Journal of Pharmacokinetics and Pharmacodynamics, vol. 43, pp. S88-S88, 2016.
[135]
C. Zhang et al., "Investigating the Combinatory Effects of Biological Networks on Gene Co-expression," Frontiers in Physiology, vol. 7, 2016.
[136]
E. Bjornson, J. Boren and A. Mardinoglu, "Personalized Cardiovascular Disease Prediction and Treatment-A Review of Existing Strategies and Novel Systems Medicine Tools," Frontiers in Physiology, vol. 7, 2016.
[137]
I. E. Elsemman et al., "Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism," Molecular Biosystems, vol. 12, no. 5, pp. 1496-1506, 2016.
[138]
M. Uhlén et al., "Transcriptomics resources of human tissues and organs," Molecular Systems Biology, vol. 12, no. 4, 2016.
[139]
P. Ghaffari, A. Mardinoglu and J. Nielsen, "Cancer Metabolism : A Modeling Perspective," Frontiers in Physiology, vol. 6, 2015.
[140]
A. Mardinoglu et al., "Extensive weight loss reveals distinct gene expression changes in human subcutaneous and visceral adipose tissue," Scientific Reports, vol. 5, 2015.
[141]
M. Adiels et al., "Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans," Frontiers in Physiology, vol. 6, 2015.
[142]
A. Mardinoglu et al., "The gut microbiota modulates host amino acid and glutathione metabolism in mice," Molecular Systems Biology, vol. 11, no. 10, 2015.
Konferensbidrag
[143]
M. Jocevski et al., "Harmonized Supervision of Degree Project Work," in Scholarship of Teaching and Learning 2019, 2019.
Icke refereegranskade
Artiklar
[144]
Y. Wei et al., "Editorial : Application of systems biology in molecular characterization and diagnosis of cancer, Volume II," Frontiers in Molecular Biosciences, vol. 9, 2022.
[145]
S. Lee et al., "In-depth shotgun metagenomic analysis of the oral and gut microbiome identifies striking overlap in microbial community structure, virulence factors and antimicrobial resistance genes based on stage and severity of cirrhosis," Journal of Hepatology, vol. 77, pp. S68-S69, 2022.
[146]
E. B. Emanuelsson et al., "MRI Characterization Of Skeletal Muscle Size And Fatty Infiltration In Long-term Trained And Untrained Individuals," Medicine & Science in Sports & Exercise, vol. 54, no. 9, pp. 389-389, 2022.
[147]
S. M. Reitzner et al., "Metabolomic Response To Acute Endurance And Resistance Exercise In Life-long Trained Athletes And Untrained Individuals," Medicine & Science in Sports & Exercise, vol. 54, no. 9, pp. 628-628, 2022.
[148]
M. Chapman et al., "Skeletal Muscle Proteomics Comparison Between Long-term Trained And Untrained Men And Women," Medicine & Science in Sports & Exercise, vol. 54, no. 9, pp. 392-393, 2022.
[149]
C. Zhang et al., "Editorial : Application of Systems Biology in Molecular Characterization and Diagnosis of Cancer," Frontiers in Molecular Biosciences, vol. 8, 2021.
[150]
S. Lee et al., "In-depth shotgun metagenomic analysis of the gut microbiome identifies striking variations in microbial community structure based on severity and stage of cirrhosis," Journal of Hepatology, vol. 75, pp. S222-S223, 2021.
[151]
M. Sinha et al., "Editorial : Redox Homeostasis and Cancer," Oxidative Medicine and Cellular Longevity, vol. 2020, 2020.
[152]
M. Svensson et al., "Associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naive esophageal and gastric adenocarcinoma.," Journal of Clinical Oncology, vol. 36, no. 4, 2018.
[153]
A. Mardinoglu, M. Uhlen and J. Boren, "Broad Views of Non-alcoholic Fatty Liver Disease," CELL SYSTEMS, vol. 6, no. 1, pp. 7-9, 2018.
[154]
J. Cao et al., "Principles of Systems Biology, No. 21," CELL SYSTEMS, vol. 5, no. 3, pp. 158-160, 2017.
[155]
A. Mardinoglu, J. Boren and U. Smith, "Confounding Effects of Metformin on the Human Gut Microbiome in Type 2 Diabetes," Cell Metabolism, vol. 23, no. 1, pp. 10-12, 2016.
[156]
A. Mardinoglu and J. Nielsen, "Editorial : The Impact of Systems Medicine on Human Health and Disease," Frontiers in Physiology, vol. 7, 2016.
Kapitel i böcker
[157]
H. Türkez, M. E. Arslan and A. Mardinoglu, "Pivotal role of micronucleus test in drug discovery," in Micronucleus Assay : An Overview, : Nova Science Publishers, Inc., 2019, pp. 49-73.
Övriga
[158]
M. Karlsson et al., "Genome-wide single cell annotation of the human protein-coding genes," (Manuscript).
[159]
[160]
D. Mahdessian et al., "Spatiotemporal dissection of the cell cycle regulated human proteome," (Manuscript).
[161]
N. Thalén et al., "Systems biology greatly improve activity of secreted therapeutic sulfatase in CHO bioprocess," (Manuscript).
Senaste synkning med DiVA:
2023-03-23 01:06:41